TB-500 (frag. 17-23) 10mg
TB-500 – synthetic fragment (17-23) of thymosin beta-4, studied for cell migration and soft tissue. Price and batch analysis.
49.00 EUR · In stock
This product is intended solely for scientific and research use, as well as for use as a reference standard in HPLC analysis, and is not an approved medicinal product. It is not intended for the diagnosis, treatment or prevention of disease in humans or animals. It has not been approved by the FDA, the EMA or any national regulator. The information on this page is provided for scientific information purposes only and does not constitute medical advice, a recommendation for use, or any claim of clinical efficacy or safety.
TB-500 – what the peptide is
TB-500 is a synthetic peptide that reproduces the active site of thymosin beta-4 – a natural 43-amino-acid protein found in almost all human cells and in the highest concentrations in platelets and wound fluid.
The synthetic fragment covers the sequence responsible for actin binding, rather than the entire protein. This is also the reason the compound is designated as fragment 17-23 – according to the position of the segment in the parent molecule.
Scientific interest in the peptide stems from the role of actin in cell motility – a property that determines the cells' ability to migrate toward a site of damage.
Mechanism of Action
The central mechanism described is binding to G-actin and participation in regulating the balance between it and the polymerized F-form. This balance determines the cell's ability to change shape and move.
From this function arise the observations on endothelial cell migration, which is a prerequisite for the formation of new blood vessels. The literature also describes a connection with the differentiation of cells involved in the recovery process.
An influence on the inflammatory response in the area of damage is also discussed, although data in this direction are fewer and more heterogeneous.
Research Data and Observations
Observations cover models of muscle and cardiac tissue, corneal, and skin injury. Differences in the rate of wound defect closure compared to controls are reported.
A separate line examines the concentrations of natural thymosin beta-4 in wound fluid and their relationship to the stages of recovery. These works are descriptive and do not track external application.
The translation of results from animal models to human conditions remains the main limitation noted in the publications.
When interpreting the published data, the difference between preclinical and clinical conditions should be taken into account. Results from cell cultures and animal models describe mechanism but do not allow quantitative conclusions for human conditions.
The dose ranges used in preclinical studies are often not directly translatable due to differences in metabolism between species. This limitation is consistently noted in review papers.
Example Calculations
The calculations below are solely mathematical examples showing the relationship between the total amount of substance, the volume of solvent, and the resulting concentration. They do not represent a recommendation for dosing, administration schedule, or instructions for use.
When dissolving 10 mg with 2 ml of bacteriostatic water:
The resulting concentration is 5 mg/ml, with 0.20 ml containing 1 mg of substance.
Example values:
- 0.1 ml = 0.5 mg
- 0.2 ml = 1 mg
- 0.3 ml = 1.5 mg
- 0.4 ml = 2 mg
- 0.5 ml = 2.5 mg
Overview of Scientific Publications
The literature on thymosin beta-4 as a natural protein is significantly more extensive than that on the synthetic fragment. The two groups of studies are not directly interchangeable, since the whole protein and the fragment differ in size and pharmacokinetic profile.
Review publications note that some of the properties attributed to the fragment originate from works on the whole protein.
Safety Data from Studies
Controlled tolerability data in humans have not been published. Available observations originate from preclinical models.
The absence of long-term studies is a significant limitation in interpreting the available literature.
A general limitation for compounds in this category is the absence of prolonged controlled studies in humans. The available information describes mechanism and short-term observations, not a safety profile for long-term use.
The product is intended exclusively for research purposes. It is not a food, dietary supplement, or medicinal product and is not intended for the diagnosis, treatment, or prevention of disease.